Page 1 of 2



Client Update

APRIL 2020

who meet the defined criteria.It will also not result in any responsibility for you	Medicare indicating that the test rage policy, effective from Decen in patient for these tests from lass o allow for continued care as we may have received. <u>bit.ly/4KMec</u> aboratories, an OPKO Health Con se call our dedicated 4Kscore® Co 3942	t was not covered. nber 30, 2019, which does provide coverage to men st year, since we did not require an ABN for the e worked with Medicare to gain the current coverage dicareAppeal npany, through its specialty oncology and urology ustomer Service team at 833-4KSCORE (833-457-2673) Immediately
 Your patient may receive a standard letter from This is not related to our current Medicare cover who meet the defined criteria. It will also not result in any responsibility for you 4Kscore® Test during the non-coverage period, t policy. Please click here for an example of the letter your patient. The 4kscore® Test is currently available at BioReference La division, GenPath. If you have any further questions, pleas or visit our website at www.4kscore.com. Aspergillus Precipitins ID, CSF Due to changes at our reference laboratory, testing for Aspergilus Precipiting ID 	Medicare indicating that the test rage policy, effective from Decen in patient for these tests from las o allow for continued care as we may have received. <u>bit.ly/4KMed</u> aboratories, an OPKO Health Con se call our dedicated 4Kscore® Co <u>3942</u> pergillus Precipitins ID, CSF was	t was not covered. nber 30, 2019, which does provide coverage to men st year, since we did not require an ABN for the e worked with Medicare to gain the current coverage dicareAppeal npany, through its specialty oncology and urology ustomer Service team at 833-4KSCORE (833-457-2673) Immediately discontinued with no alternate testing provided.
The 4kscore [®] Test is currently available at BioReference La division, GenPath. If you have any further questions, pleas or visit our website at www.4kscore.com. Aspergillus Precipitins ID, CSF Due to changes at our reference laboratory, testing for Asp	aboratories, an OPKO Health Con se call our dedicated 4Kscore® Co 3942 pergillus Precipitins ID, CSF was	npany, through its specialty oncology and urology ustomer Service team at 833-4KSCORE (833-457-2673) Immediately discontinued with no alternate testing provided.
division, GenPath. If you have any further questions, pleas or visit our website at www.4kscore.com. Aspergillus Precipitins ID, CSF Due to changes at our reference laboratory, testing for Asp	se call our dedicated 4Kscore® Cu 3942 pergillus Precipitins ID, CSF was	ustomer Service team at 833-4KSCORE (833-457-2673) Immediately discontinued with no alternate testing provided.
Due to changes at our reference laboratory, testing for As	pergillus Precipitins ID, CSF was	discontinued with no alternate testing provided.
GenArray™ Molecular Karyotyping	5306	April 1
Effective April 1, 2020, GenArray™ Molecular Karyotyping discontinued. This test, which can detect unbalanced gain a supplement to conventional cytogenetic karyotypic analy generally supplanted the utility of array CGH, typically pro-	s and losses of genomic DNA in H ysis. The advent and growth of N vides more actionable information	hematologic neoplasia, has been used as in the past as NGS (Next Generation Sequencing) testing has
Oncology Requisitions - Archival Retrieval Date Field	N/A	May 11
Oncology requisitions have been updated to include a new forms. This field should be filled out when paraffin-embed storage. The Archive Retrieval Date is the date the block w provided. It is needed for billing purposes. Also, please in	ded tissue blocks that are used f vas pulled from storage. Please	or solid tumor testing that have been taken from provide this date, if applicable, in the space
PD-L1 22C3 for Keytruda [®] for Esophageal Squamous Cell Carcinoma by IHC	TH62 (Global Only)	March 5
GenPath Oncology is pleased to now offer PD-L1 223 IHC of	clone for Esophageal Squamous	Cell Carcinoma (ESCC).
 tissues, and aids in identifying patients eligible for PD-L1 protein expression in ESCC is determined l (tumor cells, lymphocytes, macrophages) divided considered to have PD-L1 expression if CPS>=10. Keytruda (pembrolizumab) is indicated for the tr 	or treatment with the immunoth by using the Combined Positive S d by the total number of viable to reatment of patients with recurrencess PD-L1 [Combined Positive Sco	ed for use in the detection of PD-L1 protein in FFPE lerapy drug, Keytruda. Score (CPS), which is the number of PD-L1 staining cells umor cells, multiplied by 100. The specimen should be ent locally advanced or metastatic squamous cell ore (CPS) ≥10] as determined by an FDA-approved
- Please	see Test Information on Next Po	age -

GenPath and Laboratorio Buena Salud are business units of Bioreference Laboratories, Inc | © 2020 All rights reserved. 481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference Laboratories and its business units. If you have received this message in error or wish to be removed from our customer list, please call 1-888-681-5252, enter document number 700144 and follow the prompts, or send an unsubscribe fax to 1-201-663-4106 attn. J Ettinger. If you would like to subscribe to receive these updates via email, please visit http://bioreferencelabs.bioreference.com/go-green.

Page 2 of 2



Client Update

APRIL 2020

New Test InfSpecimen RequirementsBLK – FormaTurn Around Time*2 daysTransportation TemperatureShip with colMethodologyImmunohistoCollection InstructionsBLK: This corCPT Code(s)**88360x1List Price\$475D-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHCGenPath Oncology is pleased to now offer PD-L1 22PD-L1 IHC 22C3 pharmDx is the only cor benefit from the immunotherapy drug,PD-L1 protein expression in HNSCC is de cells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 expKeytruda is indicated for HNSCC: oIn combination with platinum HNSCC.OAs a single agent for the first-I tumors express PD-L1 [Combin o As a single agent for the treat platinum containing chemotherSpecimen RequirementsBLK Transportation TemperatureShip MethodologyImm Collection InstructionsBLK CPT Code(s)**883					
Specimen Requirements BLK – Forma Turn Around Time* 2 days Transportation Temperature Ship with col Methodology Immunohisto Collection Instructions BLK: This cor CPT Code(s)** 88360x1 List Price \$475 D-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC enPath Oncology is pleased to now offer PD-L1 2 enPath Oncology is pleased to now offer PD-L1 2 PD-L1 IHC 22C3 pharmDx is the only cor benefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: O In combination with platinum HNSCC. O As a single agent for the first-1 tumors express PD-L1 [Combin O As a single agent for the treat platinum containing chemother Methodology Imm O As a single agent for the treat platinum containing chemother Specimen Requirements BLK Turn Around Time* 2 da Transportation Temperature Ship Methodology Imm Collection Instructions BLK Collection Instructions BLK	- PD-L1 22C3 for Keytruda® for Esophageal Squamous Cell Carcinoma by IHC Continued-				
Turn Around Time* 2 days Transportation Temperature Ship with col Methodology Immunohisto Collection Instructions BLK: This cor CPT Code(s)** 88360x1 List Price \$475 O-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC enPath Oncology is pleased to now offer PD-L1 2 enPath Oncology is pleased to now offer PD-L1 2 PD-L1 IHC 22C3 pharmDx is the only cor benefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is de cells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: O In combination with platinum HNSCC. O As a single agent for the first-I tumors express PD-L1 [Combin O As a single agent for the treat platinum containing chemother Specimen Requirements BLK Turn Around Time* Z da Transportation Temperature Ship Methodology Methodology Imm Collection Instructions BLK Collection Instructions BLK	formation				
Transportation Temperature Ship with col Methodology Immunohistor Collection Instructions BLK: This cor CPT Code(s)** 88360x1 List Price \$475 D-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC PD-L1 22C3 pharmDx is the only cor enPath Oncology is pleased to now offer PD-L1 2 PD-L1 IHC 22C3 pharmDx is the only cor benefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is de cells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: O In combination with platinum HNSCC. O As a single agent for the first-l tumors express PD-L1 [Combin O As a single agent for the treati platinum containing chemother Specimen Requirements BLK Transportation Temperature Ship Methodology Imm Collection Instructions BLK Collection Instructions BLK Collection Instructions BLK	BLK – Formalin-fixed, Paraffin-embedded Tissue				
Methodology Immunohista Collection Instructions BLK: This correst CPT Code(s)** 88360x1 .ist Price \$475 O-L1 22C3 for Keytruda® for Head and Neck Square Square Immunohista PD-L1 22C3 for Keytruda® for Head and Neck Square Immunohista \$475 O-L1 22C3 for Keytruda® for Head and Neck Square Square Immunohista PD-L1 22C3 pharmDx is the only correst Immunohista PD-L1 IHC 22C3 pharmDx is the only correst Immunohista PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: Immunohista Immunohista Network Methodology As a single agent for the first-latumors express PD-L1 [Combin On the platinum containing chemothere Specimen Requirements BLK Furn Around Time* 2 data Transportation Temperature Ship Methodology Immunohista Collection Instructions BLK CPT Code(s)** 883					
Collection Instructions BLK: This cor CPT Code(s)** 88360x1 List Price \$475 O-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC enPath Oncology is pleased to now offer PD-L1 2 enPath Oncology is pleased to now offer PD-L1 2 PD-L1 IHC 22C3 pharmDx is the only cor benefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is de cells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: O In combination with platinum HNSCC. O As a single agent for the first-I tumors express PD-L1 [Combin O As a single agent for the treat platinum containing chemother Specimen Requirements BLK Fransportation Temperature Ship Methodology Imm Collection Instructions	Ship with cold pack during warm weather				
CPT Code(s)** 88360x1 .ist Price \$475 .ist Price \$475 O-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC PD-L1 22C3 pharmDx is the only correspondent from the immunotherapy drug, PD-L1 IHC 22C3 pharmDx is the only correspondent from the immunotherapy drug, PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macropshould be considered to have PD-L1 expression with platinum HNSCC. In combination with platinum HNSCC. In combination with platinum HNSCC. As a single agent for the first-l tumors express PD-L1 [Combino As a single agent for the treated platinum containing chemotherapy drug, Platinum Containing chemotherapy drug, Imm Collection Instructions	Immunohistochemistry				
ist Price \$475 O-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC PD-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC enPath Oncology is pleased to now offer PD-L1 7 PD-L1 IHC 22C3 pharmDx is the only correspondent from the immunotherapy drug, PD-L1 IHC 22C3 pharmDx is the only correspondent from the immunotherapy drug, PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macropshould be considered to have PD-L1 expression in the combination with platinum HNSCC. In combination with platinum HNSCC. In combination with platinum HNSCC. As a single agent for the first-tumors express PD-L1 [Combin On As a single agent for the treated platinum containing chemother the first strumors express PD-L1 [Combin Containing chemother the first strumors express PD-L1 [Combin On As a single agent for the treated platinum containing chemother the first strumors express PD-L1 [Combin On As a single agent for the treated platinum containing chemother the first strumors express PD-L1 [Combin On As a single agent for the treated platinum containing chemother the platinum containing chemothe	BLK: This comes in block form from client with surgical number imprint				
D-L1 22C3 for Keytruda® for Head and Neck Squarcinoma by IHC enPath Oncology is pleased to now offer PD-L1 7 • PD-L1 IHC 22C3 pharmDx is the only cord benefit from the immunotherapy drug, • PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 expression in the sindicated for HNSCC: • In combination with platinum HNSCC. • As a single agent for the first-tumors express PD-L1 [Combin 0 • As a single agent for the treat platinum containing chemotherapy • Mev • Specimen Requirements BLK Fransportation Temperature Ship Methodology Imm Collection Instructions BLK	· · · · · · · · · · · · · · · · · · ·				
 PD-L1 IHC 22C3 pharmDx is the only corbenefit from the immunotherapy drug, PD-L1 IHC 22C3 pharmDx is the only corbenefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macropshould be considered to have PD-L1 expression in the polatinum distribution with platinum HNSCC. As a single agent for the first-tumors express PD-L1 [Combine] As a single agent for the treated platinum containing chemotherapy Methodology Imm Collection Instructions BLK CPT Code(s)** 	\$475				
 PD-L1 IHC 22C3 pharmDx is the only corbenefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is decells (tumor cells, lymphocytes, macropshould be considered to have PD-L1 exp Keytruda is indicated for HNSCC: In combination with platinum HNSCC. As a single agent for the first-tumors express PD-L1 [Combinding of the treating platinum containing chemothered to have provided by the treating platinum containing chemothered by the treating platinum containing chemothered by the treating platinum containing chemothered by the treating the treating platinum containing chemothered by the treating p	amous Cell TH63 (Global Only) March 5				
benefit from the immunotherapy drug, PD-L1 protein expression in HNSCC is de cells (tumor cells, lymphocytes, macrop should be considered to have PD-L1 exp Keytruda is indicated for HNSCC: In combination with platinum HNSCC. As a single agent for the first-l tumors express PD-L1 [Combin As a single agent for the treating platinum containing chemother Specimen Requirements BLK Turn Around Time* 2 da Transportation Temperature Ship Methodology Imm Collection Instructions BLK	223 IHC clone for Head and Neck Squamous Cell Carcinoma (HNSCC).				
Specimen Requirements BLK Furn Around Time* 2 da Fransportation Temperature Ship Methodology Imm Collection Instructions BLK CPT Code(s)** 883	and FU for the first-line treatment of patients with metastatic or with unresectable, recurrer ine treatment of patients with metastatic or with unresectable, recurrent HNSCC whose ned Positive Score (CPS) \geq 1] as determined by an FDA-approved test. ment of patients with recurrent or metastatic HNSCC with disease progression on or after				
Turn Around Time* 2 da Transportation Temperature Ship Methodology Imm Collection Instructions BLK CPT Code(s)** 883	v Test Information				
Transportation Temperature Ship Methodology Imm Collection Instructions BLK CPT Code(s)** 883	– Formalin-fixed, Paraffin-embedded Tissue				
MethodologyImmCollection InstructionsBLKCPT Code(s)**883					
Collection InstructionsBLKCPT Code(s)**883	Ship with cold pack during warm weather				
CPT Code(s)** 883	Immunohistochemistry				
	BLK: This comes in block form from client with surgical number imprint				
	88360x1				
List Price \$47	5				
EGIONAL UPDATE - INR	1112 March 19 Normal Non-Medicated Patients for INR has been updated when performed at our Melbourn				

	Previous Test Information	New Test Information
Reference Range	0.81-1.16	0.81-1.17

NOTES:

To subscribe to receive client updates via email, please visit <u>http://bioreferencelabs.bioreference.com/go-green</u>

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

GenPath and Laboratorio Buena Salud are business units of Bioreference Laboratories, Inc | © 2020 All rights reserved. 481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference Laboratories and its business units. If you have received this message in error or wish to be removed from our customer list, please call 1-888-681-5252, enter document number 700144 and follow the prompts, or send an unsubscribe fax to 1-201-663-4106 attn. J Ettinger. If you would like to subscribe to receive these updates via email, please visit http://bioreferencelabs.bioreference.com/go-green.



GenPath and Laboratorio Buena Salud are business units of Bioreference Laboratories, Inc | © 2020 All rights reserved. 481 Edward H Ross Drive | Elmwood Park NJ 07407 | tel 800 229 5227 | fax 201 791 1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference Laboratories and its business units. If you have received this message in error or wish to be removed from our customer list, please call 1-888-681-5252, enter document number 700144 and follow the prompts, or send an unsubscribe fax to 1-201-663-4106 attn. J Ettinger. If you would like to subscribe to receive these updates via email, please visit http://bioreferencelabs.bioreference.com/go-green.